Overview
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Eligibility
Inclusion Criteria:
- Histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology
- Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy)
- Available tumor samples for centralized testing
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- Measurable disease
Exclusion Criteria:
- Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma
- Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy
- Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy)
Other protocol-defined inclusion/exclusion criteria apply